This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.
| Item | Details |
|---|---|
| A. Classification codes | ICD-10: E27.1 (primary adrenocortical insufficiency) | Special Copayment Reduction: V116 (rare disease, 10% copayment for 5 years after registration) |
| B. Synonyms | Addison disease, primary adrenocortical insufficiency, autoimmune adrenalitis, familial glucocorticoid deficiency, Addison disease, Primary adrenocortical insufficiency, Autoimmune adrenalitis, Autoimmune polyendocrinopathy (APS I/II) |
| C. Adult onset | Likelihood of first presentation in adulthood: high — autoimmune Addison disease most commonly presents in adults in their 30s~50s; symptoms appear gradually over months to years, starting with nonspecific fatigue and weight loss, so diagnosis is often delayed. |
| 1. History | 1855 first description by Thomas Addison → tuberculous and autoimmune causes elucidated → 1950s isolation and synthesis of cortisol and establishment of replacement therapy → understanding of pathophysiology through discovery of autoantibodies (21-hydroxylase antibodies). |
| 2. Causes | Autoimmune (70~90% in developed countries); tuberculous (developing countries); others — fungal infection, hemorrhagic infarction, metastatic cancer, sarcoidosis, hemochromatosis, adrenoleukodystrophy (ALD); rarely hereditary (APECED, familial adrenal insufficiency). |
| 3. Genetics | Autoimmune form is polygenic; strong association with HLA-DR3, DR4; CTLA-4, PTPN22, NLRP1, CYP21A2 variants implicated; APECED — AIRE gene, autosomal recessive; X-linked ALD (ABCD1); familial glucocorticoid deficiency (MC2R, etc.). |
| 4. General epidemiology | Prevalence about 1:10,000 (Western countries); about 2:1 in women; incidence about 6 per million per year; Korean data limited, but managed as a rare disease; the tuberculous form remains an important cause in developing countries. |
| 5. Pathophysiology | Autoimmune — 21-hydroxylase (CYP21A2)-specific T cell-mediated destruction of the adrenal cortex + autoantibody production; cortisol and aldosterone deficiency → ACTH excess → skin hyperpigmentation; aldosterone deficiency → sodium loss and potassium retention. |
| 6. Symptoms | Chronic: fatigue and weakness, weight loss, anorexia, salt craving, nausea, muscle and joint pain, depression/cognitive decline; skin/mucosal hyperpigmentation; decreased pubic and axillary hair in women; hypotension and dizziness. |
| 7. Signs | Low basal cortisol, poor response to ACTH stimulation; elevated ACTH; hyponatremia and hyperkalemia; low blood glucose; elevated plasma renin and low aldosterone; positive 21-hydroxylase autoantibodies (80%); adrenal atrophy or calcification on CT. |
| 8. Screening | Morning serum cortisol measurement with nonspecific symptoms or skin hyperpigmentation; follow-up of autoimmune high-risk groups (APS-I, APS-II); 21-hydroxylase antibody screening; VLCFA screening in males at risk of ALD. |
| 9. Diagnosis | Morning serum cortisol (<5 µg/dL diagnostic); cortisol after cosyntropin stimulation; confirmation of elevated plasma ACTH (confirms primary form); 21-OH autoantibodies; adrenal CT; electrolytes, blood glucose, renin, aldosterone. |
| 10. Treatment | Hydrocortisone (15~25 mg/day, 2~3 times daily); fludrocortisone (0.05~0.2 mg/day, correction of salt wasting); DHEA (optional); stress-dose protocol; emergency management of adrenal crisis; patient education. |
| 11. Prognosis | Normal lifespan possible with appropriate treatment; mortality risk mainly due to adrenal crisis and accompanying autoimmune diseases; quality of life reduced compared with healthy controls; can be improved with early recognition and continuous treatment. |
| 12. Prevention | Screening of autoimmune high-risk groups; stress-dose education; adrenal crisis prevention protocol; follow-up of accompanying autoimmune diseases; wearing a patient alert card. |
| 13. References | Bornstein SR et al. Diagnosis and treatment of primary adrenal insufficiency … and 9 other papers |
The history of Addison disease begins in 1855 with the monograph On the Constitutional and Local Effects of Disease of the Supra-Renal Capsules, published at Guy's Hospital in London by the English physician Thomas Addison (1793~1860). In this work, Addison observed in common among 11 patients a peculiar bronze pigmentation of the skin and mucous membranes, generalized weakness, gastrointestinal disturbances, and hypotension, and found lesions of the adrenal glands (supra-renal capsule) in all of them. Many of these cases were due to tuberculous destruction of the adrenals; at a time when the function of the adrenal glands was completely unknown, it was a historic achievement that first described the link between the adrenals and systemic abnormalities. The disease was named "Addison's disease" after him and was later replaced by the pathophysiological name "primary adrenocortical insufficiency."
In the late 19th and early 20th centuries, understanding of the physiological role of the adrenal glands gradually deepened. In 1896, George Oliver and Edward Sharpey-Schäfer discovered that adrenal medulla extract (epinephrine) raises blood pressure, which increased interest in the overall function of the adrenal glands. In the 1930s, several steroid substances began to be isolated from the adrenal cortex, and Philip Hench, Edward Kendall, and Tadeusz Reichstein isolated and synthesized cortisone and received the 1950 Nobel Prize in Physiology or Medicine. Their achievements confirmed that cortisol deficiency is the core pathophysiology of Addison disease and opened the door to the treatment of corticosteroid replacement therapy.
From the 1950s onward, with the establishment of oral replacement therapy using cortisol (hydrocortisone) and fludrocortisone, Addison disease was transformed from a fatal disease into a manageable chronic disease. In the 1960s, autoimmunity began to emerge as the main cause of Addison disease. In 1963, Anderson et al. first discovered adrenocortical autoantibodies in patients with Addison disease, and methods for detecting anti-adrenocortical antibodies by immunofluorescence were subsequently developed. In 1992, Winqvist et al. identified 21-hydroxylase (CYP21A2) as the main autoantigen of Addison disease, and the pathophysiology of autoimmune adrenalitis began to be understood at the molecular level.
In the 1980s, the association with autoimmune polyglandular syndrome (APS) was systematized, establishing that Addison disease is a core component of APS-II, clustering with type 1 diabetes, autoimmune thyroid disease, pernicious anemia, and others. It was also established that Addison disease is a core feature of autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED/APS-I) caused by AIRE gene deficiency. In Korea, Addison disease began to be described in endocrinology textbooks from the 1980s~90s, and since the 2010s a systematic management system has been built together with rare disease Special Copayment Reduction (V116) registration. With the decline of tuberculosis, autoimmune causes are gradually becoming predominant in Korea as well.
The causes of Addison disease (primary adrenocortical insufficiency) are destruction or loss of function of the adrenal cortex itself, with various etiologic causes.
Autoimmune Adrenalitis
This is the most common cause, accounting for 70~90% of all Addison disease in developed countries. An autoimmune reaction against the adrenal cortex gradually destroys the adrenocortical cells that produce cortisol, aldosterone, and DHEA. The main autoantigen is 21-hydroxylase (CYP21A2), and autoantibodies against it (anti-21-OH antibodies) are detected in about 80~90% of patients. Both T cell-mediated cytotoxicity and autoantibodies are understood to be involved. Autoimmune adrenalitis is strongly associated with the HLA-DR3 and DR4 haplotypes and commonly accompanies other autoimmune diseases (autoimmune thyroid disease, type 1 diabetes, pernicious anemia, vitiligo, premature ovarian failure, etc.). Such co-occurrence is called autoimmune polyglandular syndrome (APS-I, APS-II).
Tuberculous adrenal destruction
Historically the most common cause of Addison disease, its frequency has decreased greatly in developed countries with advances in antituberculosis treatment. In regions with relatively high tuberculosis prevalence, including Korea, it is still one of the important causes. Mycobacterium tuberculosis disseminates hematogenously to the adrenal glands, causing granulomatous inflammation and caseous necrosis that destroy both adrenals. On adrenal CT, adrenal enlargement and calcification in the early stage, and atrophy and calcification in the chronic stage, are characteristic.
Other infectious causes
Deep fungal infections such as histoplasmosis, coccidioidomycosis, and paracoccidioidomycosis; CMV (in immunocompromised patients); HIV-associated adrenal opportunistic infections; bilateral adrenal hemorrhagic infarction due to meningococcal sepsis (Waterhouse-Friderichsen syndrome).
Adrenal hemorrhage and infarction
Bilateral adrenal infarction due to bleeding during anticoagulant therapy, antiphospholipid antibody syndrome, thromboembolism, or sepsis.
Adrenal infiltration and metastasis
Adrenal insufficiency occurs when adrenal metastases from lung cancer, breast cancer, gastrointestinal cancer, renal cell carcinoma, and others destroy more than 90% of the adrenal glands. Lymphoma, sarcoidosis, and hemochromatosis are also rare causes.
Hereditary causes
These include X-linked adrenoleukodystrophy (ALD, ABCD1 gene deficiency), APECED/APS-I (AIRE gene deficiency), familial glucocorticoid deficiency (MC2R, MRAP, NNT genes), POEMS syndrome, and DAX-1 (NR0B1) gene deficiency (congenital adrenal hypoplasia and central hypogonadism).
The genetic basis of Addison disease is broadly divided into autoimmune causes and hereditary causes.
Genetic predisposition to autoimmune Addison disease
Autoimmune Addison disease is a complex disease with a polygenic genetic predisposition. The strongest genetic risk factor is the HLA complex. HLA-DRB1*03:01 (DR3) and HLA-DRB1*04:01 (DR4) each increase the risk of autoimmune Addison disease about 5~6-fold. The risk is higher when both alleles are carried (DR3/DR4 heterozygosity). HLA-DQB1*02 and DQB1*03:02 are also reported as risk factors.
Non-HLA genes confirmed as significant risk factors in association studies include CTLA-4 (cytotoxic T-lymphocyte-associated protein 4; an immune-suppressive regulatory gene), PTPN22 (protein tyrosine phosphatase non-receptor type 22; regulation of T-cell signaling), TNFRSF4 (OX40L), and NLRP1 (autoimmune regulation). There are also reports that the risk of autoimmune adrenalitis is increased in carriers of CYP21A2 gene variants.
APECED/APS-I (AIRE gene, OMIM #240300)
A monogenic disease caused by autosomal recessive variants of the autoimmune regulator gene (AIRE). AIRE is key to maintaining central tolerance by expressing peripheral tissue antigens in thymic medullary epithelial cells to eliminate autoreactive T cells. In AIRE deficiency, autoreactive T cells are released into the periphery and autoimmunity against various organs develops. Clinically, three features—mucocutaneous candidiasis, hypoparathyroidism, and Addison disease—form a triad (diagnosed with at least 2). The AIRE gene is located on the long arm of chromosome 21 (21q22.3), and R257X in exon 8 (the Finnish founder variant) is the most common in Finland.
X-linked adrenoleukodystrophy (ALD, ABCD1 gene)
X-linked recessive variants of the ABCD1 gene (Xq28), which encodes ATP-binding cassette transporter D1 involved in transport of very long-chain fatty acids (VLCFA). In males, adrenal insufficiency (65%) and neural demyelination (adrenoleukodystrophy/adrenomyeloneuropathy) appear, and mild neurological symptoms are possible even in female carriers. Diagnosis is screened by measurement of plasma VLCFA (C26:0, C24:0/C22:0 ratio).
Familial glucocorticoid deficiency (FGD)
A rare autosomal recessive disease caused by variants in the MC2R (ACTH receptor, OMIM #607397), MRAP (MC2R accessory protein, OMIM #607398), NNT (nicotinamide nucleotide transhydrogenase), STAR, and CYP11A1 genes. It is characterized by severe cortisol deficiency but preserved aldosterone secretion, so there is no salt wasting.
Addison disease is a rare endocrine disease with an estimated worldwide prevalence of about 1:10,000 (100 per 100,000). According to well-studied data from Scandinavian countries, the prevalence is about 144 per million in Norway, about 110 per million in the UK, and about 144 per million in Denmark. The annual incidence is reported at about 5~6 per million per year.
Sex distribution: Autoimmune Addison disease occurs about twice as frequently in women. However, tuberculous causes show no clear sex difference, and ALD, being an X-linked disease, occurs mainly in males.
Age of onset: Autoimmune Addison disease can occur at any age but is most commonly diagnosed in the 30s~50s. APS-I (APECED) often presents in early childhood (average before age 10).
Epidemiology in Korea: Systematic research data on the prevalence of Addison disease in Korea are limited. Since the 2010s, it can be assessed through rare disease Special Copayment Reduction registration data, but published aggregate data are limited. In Korea, tuberculosis was formerly the main cause, but with declining tuberculosis prevalence, autoimmune causes are relatively increasing. In Health Insurance Review & Assessment Service (HIRA) data, the number of patients treated under code E27.1 is estimated to be in the thousands.
Accompanying autoimmune diseases: Other autoimmune diseases accompany about 50% of patients with autoimmune Addison disease. In APS-II, autoimmune thyroid disease (Hashimoto's thyroiditis or Graves' disease, about 50%), type 1 diabetes (about 15%), pernicious anemia (about 5%), vitiligo, and premature ovarian failure (about 10%) accompany. Screening tests for these accompanying diseases are recommended regularly after the diagnosis of Addison disease.
The pathophysiology of autoimmune Addison disease is progressive destruction of the adrenal cortex due to immunological attack against it.
Initiation and progression of the autoimmune response
In individuals with genetic predisposition (especially HLA-DR3/DR4), an autoimmune response is initiated by environmental triggers (infection, stress, etc., not yet fully elucidated). CYP21A2, a steroidogenic enzyme of the adrenal cortex, is the main autoantigen, and autoreactive CD4⁺ and CD8⁺ T cells against it escape negative selection in the thymus and come to be present in peripheral blood. When they recognize and attack adrenocortical cells, the adrenocortical cells are progressively destroyed. At the same time, anti-21-OH autoantibodies are produced by B cells, contributing to complement-dependent cytotoxicity and antibody-dependent cellular cytotoxicity (ADCC) against adrenocortical cells.
Stepwise progression of adrenocortical destruction
Autoimmune adrenal destruction progresses gradually over months to years through the following stages. ① Autoantibodies present but adrenal function normal → ② reduced adrenal response to ACTH stimulation (latent adrenal insufficiency) → ③ low basal cortisol, elevated ACTH, and aldosterone beginning to rise → ④ complete adrenal insufficiency (deficiency of both cortisol and aldosterone). This stepwise progression causes diagnostic delay and explains how acute adrenal crisis occurs when exposed to stressful situations in the latent stage.
Pathophysiological consequences of cortisol deficiency
Cortisol is essential for various metabolic functions, including gluconeogenesis, lipolysis, protein catabolism, immune regulation, and maintenance of blood pressure. In deficiency, fasting hypoglycemia, weight loss, fatigue, immune dysfunction, and hypotension appear. Cortisol deficiency causes loss of hypothalamic-pituitary negative feedback, so ACTH is chronically oversecreted. α-MSH (melanocortin), derived from POMC (pro-opiomelanocortin), the ACTH precursor, stimulates melanin production via the melanocortin-1 receptor, producing the characteristic hyperpigmentation of the skin and mucous membranes.
Pathophysiological consequences of aldosterone deficiency
Aldosterone deficiency reduces sodium reabsorption and reduces potassium and hydrogen ion secretion in the distal tubule and collecting duct → hyponatremia, hyperkalemia, metabolic acidosis, dehydration, and hypotension develop. Elevated plasma renin activity with inappropriately low aldosterone is the characteristic biochemical finding of primary adrenal insufficiency.
The symptoms of Addison disease are mostly nonspecific chronic symptoms that progress gradually over months to years, so it is not uncommon for diagnosis to be delayed by years.
Chronic symptoms
Hyperpigmentation of the skin and mucous membranes — the characteristic finding of Addison disease
Due to ACTH and MSH excess, melanin synthesis increases, and characteristic hyperpigmentation appears in the skin and mucous membranes. Areas exposed to natural light (face, neck, backs of the hands), areas subject to pressure (elbows, knees, palmar creases, heels), skin folds, scars, nipples, and genital skin are mainly affected. Blue-black pigmented patches of the oral mucosa (buccal mucosa, gums, tongue, palate) are very characteristic. Hyperpigmentation appears only in primary adrenal insufficiency (because of ACTH excess) and does not appear in central adrenal insufficiency of pituitary origin (secondary, tertiary).
Symptoms of acute exacerbation
When cortisol requirements increase sharply in stressful situations (infection, surgery, trauma, dehydration), acute adrenal crisis (Addisonian crisis) can occur, which is classified separately as E27.2. Symptoms include severe abdominal pain, nausea, vomiting, a sharp drop in blood pressure, hypoglycemia, hyperkalemia, hyponatremia, and decreased consciousness.
Objective findings of Addison disease are confirmed through physical examination, biochemical testing, and imaging.
Physical examination findings
Biochemical findings
Imaging findings
No systematic screening program for early detection of Addison disease has yet been standardized. However, active screening is recommended in situations of clinical suspicion and in high-risk groups.
Situations of high clinical suspicion
Screening of autoimmune high-risk groups
Screening of X-linked ALD high-risk groups
Screen all brothers and sons of male patients with confirmed ALD by measuring plasma VLCFA (C26:0, C26:0/C22:0 ratio). If positive, confirm with ABCD1 gene testing. Screening is also needed in sons of female ALD carriers.
Initial screening test
When suspected, the first test performed is 8 a.m. serum cortisol. If cortisol is below 5 µg/dL, adrenal insufficiency is strongly suspected and is confirmed with an ACTH stimulation test. If cortisol is 18 µg/dL or higher, adrenal insufficiency can be virtually excluded. In the intermediate range (5~18 µg/dL), an ACTH stimulation test is needed if symptoms are present.
Diagnosis of Addison disease is made by an integrated approach of biochemical, immunological, and imaging tests that includes the following steps.
Step 1: Confirm adrenal insufficiency
Step 2: Differentiate primary (adrenal) vs. central (pituitary/hypothalamic)
Step 3: Identify the cause
Step 4: Evaluate accompanying autoimmune diseases
The treatment goals of Addison disease are to replace the deficient steroid hormones as physiologically as possible, prevent adrenal crisis, and maintain quality of life.
Glucocorticoid replacement therapy
Hydrocortisone is recommended as the first-line agent. To mimic the physiological cortisol secretion pattern (high in the morning, low in the afternoon~evening), it is given in 2~3 divided doses daily. The usual maintenance dose is 15~25 mg/day (10~15 mg in the morning, 5~10 mg in the afternoon, optionally 5 mg in the evening). The lowest effective dose is used to avoid overtreatment. Long-term overdosing carries a risk of Cushing syndrome-like complications (weight gain, diabetes, osteoporosis, hypertension). Modified-release hydrocortisone (Plenadren) mimics the physiological pattern more closely with once-daily dosing and is licensed in some countries. In adults, prednisolone (3~5 mg/day) and dexamethasone (0.25~0.5 mg/day) can also be used as alternatives, but the risk of overtreatment is higher.
Mineralocorticoid replacement therapy
Fludrocortisone 0.05~0.2 mg/day, given once daily. The dose is adjusted by monitoring blood pressure, serum electrolytes, and plasma renin activity. The goal is to keep renin within the upper part of the normal reference range. In hot climates or during activities with heavy sweating, a dose increase or salt supplementation is needed.
DHEA supplementation (optional)
In women, DHEA 25~50 mg/day (oral) may be tried when fatigue, low libido, and reduced quality of life persist. Considered when serum DHEA-S is at or below the lower limit of the normal range. It may be particularly useful for women in whom adrenal androgen deficiency affects quality of life and psychological well-being, but is generally unnecessary in men.
Stress-dose protocol (Sick Day Rules)
This is the key to preventing adrenal crisis. In situations of physical stress such as fever (38°C or higher), nausea and vomiting, surgical procedures, trauma, and childbirth, the hydrocortisone dose is increased 2~3-fold. When oral intake is not possible, hydrocortisone 100 mg is given immediately by intravenous or intramuscular injection. All patients should always carry emergency hydrocortisone injection (100 mg ampule or self-injection kit) and wear a medical alert card or bracelet. A perioperative steroid coverage protocol must also be arranged in advance with the anesthesiologist and surgeon.
Additional treatment according to cause
Tuberculous adrenalitis — antituberculosis treatment. ALD — Lorenzo's oil (partial suppression of neurological progression), bone marrow transplantation (in early cerebral ALD), gene therapy (investigational). APECED — besides glucocorticoid/aldosterone replacement, treatment of oral candidiasis (fluconazole) and correction of hypocalcemia.
When appropriate hormone replacement therapy is provided, the survival of patients with Addison disease improves markedly, and survival close to a normal lifespan is possible. However, because of the limitations of treatment and various complications, attention to quality of life and long-term prognosis is needed.
Mortality risk
Before modern treatment, Addison disease had a high case fatality rate, but survival has now improved greatly with appropriate treatment. However, population-based cohort studies report that mortality in patients with Addison disease is about 2-fold higher than in the general population. The main causes of excess mortality are ① acute adrenal crisis (failure to increase the steroid dose in infectious or acute stress situations), ② accompanying cardiovascular disease, ③ infectious complications, and ④ neurological complications in ALD.
Risk of adrenal crisis
Adrenal crisis occurs at a frequency of 10~14/100 patient-years, of which fatal crises are reported at 0.5/100 patient-years. Most are preventable with appropriate patient education and adherence to the stress-dose protocol. Fever, infection, and surgery are the most common precipitating factors.
Quality of life
Fatigue, sleep disturbance, cognitive decline, and sexual dysfunction often persist even during treatment, so quality of life is lower than in healthy controls. One reason pointed out is that current hydrocortisone replacement therapy does not fully reproduce the physiological pattern of cortisol secretion. New administration methods such as modified-release hydrocortisone and continuous subcutaneous infusion (CSCI) are being studied with the aim of improving quality of life.
Metabolic and cardiovascular prognosis
Hydrocortisone overdosing increases the risk of obesity, diabetes, osteoporosis, and hypertension. Regular monitoring of body mass index, blood pressure, blood glucose, and bone density is recommended. Using the lowest effective dose is key to preventing these complications.
Prevention in Addison disease focuses on early detection and prevention of acute complications (adrenal crisis) rather than prevention of the disease itself.
Primary prevention: monitoring of high-risk groups
There is currently no way to completely prevent the development of autoimmune adrenalitis. Latent adrenal insufficiency is detected early by regular screening of 21-OH antibodies and morning cortisol in patients with other autoimmune diseases (especially APS-II component diseases — type 1 diabetes, autoimmune thyroid disease), patients with APECED, and males at risk of ALD. In tuberculosis-endemic areas, early detection and treatment of tuberculosis is important for preventing tuberculous Addison disease.
Secondary prevention: early diagnosis and adrenal crisis prevention education
Comprehensive patient education immediately upon diagnosis is essential. Education content: ① the stress-dose protocol (2~3-fold increase of hydrocortisone with fever, vomiting, or surgery), ② how to self-inject intramuscularly when oral intake is not possible, ③ criteria for immediate emergency department visit (vomiting persisting 2 or more times so that oral medication is impossible, decreased consciousness, extreme weakness), ④ wearing a medical alert card or bracelet, ⑤ always carrying hydrocortisone injection. Information about this emergency is also shared with the patient's family and workplace or school.
Tertiary prevention: monitoring of long-term complications
At regular outpatient follow-up (at least 1~2 times a year), the following are evaluated: adequacy of the hydrocortisone dose (adjusted based on weight, blood pressure, and fatigue level), fludrocortisone dose adjustment (based on blood pressure, electrolytes, and renin), bone density (DXA, every 2~3 years), blood pressure, blood glucose, and lipid profile, and screening for accompanying autoimmune diseases (thyroid, blood glucose, vitamin B12, sex hormones). Monitoring for signs of androgen excess in women receiving DHEA supplementation is also included.
Bornstein SR, Allolio B, Arlt W, et al. Diagnosis and treatment of primary adrenal insufficiency: An Endocrine Society clinical practice guideline. Journal of Clinical Endocrinology & Metabolism. 2016;101(2):364–389. DOI: 10.1210/jc.2015-1710. PMID: 26760044.
Addison T. On the Constitutional and Local Effects of Disease of the Supra-Renal Capsules. London: Samuel Highley; 1855. (Historical primary source — no PMID.)
Charmandari E, Nicolaides NC, Chrousos GP. Adrenal insufficiency. Lancet. 2014;383(9935):2152–2167. DOI: 10.1016/S0140-6736(13)61684-0. PMID: 24503135.
Husebye ES, Allolio B, Arlt W, et al. Consensus statement on the diagnosis, treatment and follow-up of patients with primary adrenal insufficiency. Journal of Internal Medicine. 2014;275(2):104–115. DOI: 10.1111/joim.12162. PMID: 24330030.
Betterle C, Dal Pra C, Mantero F, Zanchetta R. Autoimmune adrenal insufficiency and autoimmune polyendocrine syndromes: autoantibodies, autoantigens, and their applicability in diagnosis and disease prediction. Endocrine Reviews. 2002;23(3):327–364. DOI: 10.1210/edrv.23.3.0466. PMID: 12050123.
Erichsen MM, Løvås K, Skinningsrud B, et al. Clinical, immunological, and genetic features of autoimmune primary adrenal insufficiency: observations from a Norwegian registry. Journal of Clinical Endocrinology & Metabolism. 2009;94(12):4882–4890. DOI: 10.1210/jc.2009-1368. PMID: 19858318.
Quinkler M, Beuschlein F, Hahner S, et al. Adrenal cortical insufficiency — a life threatening illness with multiple etiologies. Deutsches Ärzteblatt International. 2013;110(51–52):882–888. DOI: 10.3238/arztebl.2013.0882. PMID: 24418389.
Bleicken B, Hahner S, Ventz M, Quinkler M. Impaired subjective health status in 256 patients with adrenal insufficiency on standard therapy based on cross-sectional analysis. Journal of Clinical Endocrinology & Metabolism. 2010;95(9):4254–4260. DOI: 10.1210/jc.2009-2421. PMID: 20534765.
Hahner S, Loeffler M, Bleicken B, et al. Epidemiology of adrenal crisis in chronic adrenal insufficiency: the need for new prevention strategies. European Journal of Endocrinology. 2010;162(3):597–602. DOI: 10.1530/EJE-09-0876. PMID: 20022946.
Bergthorsdottir R, Leonsson-Zachrisson M, Odén A, Johannsson G. Premature mortality in patients with Addison's disease: a population-based study. Journal of Clinical Endocrinology & Metabolism. 2006;91(12):4849–4853. DOI: 10.1210/jc.2006-0076. PMID: 16968806.